Cargando…

Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD

BACKGROUND: Glucocorticoids are commonly prescribed to treat inflammation of the respiratory system; however, they are mostly ineffective for controlling chronic obstructive pulmonary disease (COPD)-associated inflammation. This study aimed to elucidate the molecular mechanisms responsible for such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reddy, Aravind T, Lakshmi, Sowmya P, Banno, Asoka, Reddy, Raju C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969699/ https://www.ncbi.nlm.nih.gov/pubmed/32021151 http://dx.doi.org/10.2147/COPD.S230188

Ejemplares similares

PPAR Agonists for the Prevention and Treatment of Lung Cancer
por: Lakshmi, Sowmya P., et al.
Publicado: (2017)

Cigarette smoke downregulates Nur77 to exacerbate inflammation in chronic obstructive pulmonary disease (COPD)
por: Reddy, Aravind T., et al.
Publicado: (2020)

Emerging pharmaceutical therapies for COPD
por: Lakshmi, Sowmya P, et al.
Publicado: (2017)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

The Nitrated Fatty Acid 10-Nitro-oleate Diminishes Severity of LPS-Induced Acute Lung Injury in Mice
por: Reddy, Aravind T., et al.
Publicado: (2012)

PPARγ in Bacterial Infections: A Friend or Foe?
por: Reddy, Aravind T., et al.
Publicado: (2016)

PPARγ as a Novel Therapeutic Target in Lung Cancer
por: Reddy, Aravind T., et al.
Publicado: (2016)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Nitrated Fatty Acids Reverse Cigarette Smoke-Induced Alveolar Macrophage Activation and Inhibit Protease Activity via Electrophilic S-Alkylation
por: Reddy, Aravind T., et al.
Publicado: (2016)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Endothelial glucocorticoid receptor promoter methylation according to dexamethasone sensitivity
por: Mata-Greenwood, Eugenia, et al.
Publicado: (2015)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Transcriptome Responses to Dexamethasone Depending on Dose and Glucocorticoid Receptor Sensitivity in the Liver
por: Murani, Eduard, et al.
Publicado: (2019)

Dexamethasone Inhibits Synergistic Induction of PDE4B Expression by Roflumilast and Bacterium NTHi
por: Lee, Byung-Cheol, et al.
Publicado: (2018)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist
por: Milara, Javier, et al.
Publicado: (2015)

Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations
por: Field, Stephen K.
Publicado: (2011)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015)

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
por: Yuan, Lianfang, et al.
Publicado: (2016)

Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
por: Watz, Henrik, et al.
Publicado: (2018)

A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers
por: Matencio, Adrián, et al.
Publicado: (2019)

The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020)

Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor–induced dipeptidase-1 expression and glutathione depletion
por: von Mässenhausen, Anne, et al.
Publicado: (2022)

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011)

Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”
Publicado: (2012)

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol
por: Calverley, Peter MA, et al.
Publicado: (2012)

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
por: Moll, Keran, et al.
Publicado: (2015)

Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA
por: Kardos, Peter, et al.
Publicado: (2018)

Interaction of Glucocorticoid Receptor (GR) with Estrogen Receptor (ER) α and Activator Protein 1 (AP1) in Dexamethasone-mediated Interference of ERα Activity
por: Karmakar, Sudipan, et al.
Publicado: (2013)

RNA binding by the glucocorticoid receptor attenuates dexamethasone-induced gene activation
por: Lammer, Nickolaus C., et al.
Publicado: (2023)

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom
por: Samyshkin, Yevgeniy, et al.
Publicado: (2013)

Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice
por: Raju, S. Vamsee, et al.
Publicado: (2017)

Effects of hypoxia inducible factor-1α on apoptotic inhibition and glucocorticoid receptor downregulation by dexamethasone in AtT-20 cells
por: Zhang, Chenran, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ma5n5igl9idgntg515rm733vuo